Lung Cancer Clinical Trial
Official title:
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
It has been shown in previous studies that the ability to treat lung cancer could be
significantly improved by not only targeting the tumor cells directly with chemotherapy, but
also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor
are formed through a process called angiogenesis. Vandetanib is an investigational drug that
acts by producing what is called an anti-angiogenic effect. An Anti-angiogenic effect is able
to inhibit the development of new blood vessels required by tumors to survive by blocking the
growth factors needed to form new blood vessels.
The purpose of this study is to determine if the addition of vandetanib to a standard
chemotherapy regimen will slow or stop the growth of the cancer for a longer period of time
compared to the time period generally gained from the use of standard chemotherapy alone
Lung cancer is the number one cause of cancer-related mortality in the United States, with an
estimated 160,390 deaths in 2007. Over 80% of these patients will have non-small cell lung
cancer (NSCLC), and the majority of these patients have advanced disease at the time of
diagnosis.
Patients with advanced disease who have an adequate performance status clearly benefit from
systemic chemotherapy, and many clinical trials have been carried out to determine the most
effective regimen. Comorbidities associated with NSCLC preclude the use of cisplatin in
doublet therapies, and, a meta-analysis comparing platinum-based doublet regimens to
non-platinum based, third generation regimens revealed that survival outcomes between these
regimens were equivalent. Despite poor response and overall survival benefits in this patient
population with accepted treatment doublets, the addition of a third cytotoxic agent did not
improve survival and demonstrated increased toxicity. Therefore, it appears a threshold
maximum response can be gained with cytotoxic chemotherapy alone. However, the poor outcomes
still associated with advanced NSCLC clearly demanded the need for continued improvements in
treatment. It was postulated that anticancer therapy could be significantly improved by not
only targeting the tumor cells directly, but also by targeting neo-angiogenesis. A randomized
phase II trial demonstrated a significant improvement in time to progression (TTP) in
patients receiving carboplatin, paclitaxel and bevacizumab compared to chemotherapy alone.
Due to life-threatening and fatal hemorrhage patients with squamous cell histology, as well
as those with a prior history of hemoptysis and brain metastases were excluded from all
further clinical trials using bevacizumab. The definitive study of bevacizumab in NSCLC was a
randomized phase III clinical trial conducted by ECOG (E4599) in which patients with advanced
non-squamous NSCLC received carboplatin + paclitaxel with or without bevacizumab which met
the clinical endpoint of improvement in survival and led to the approval of bevacizumab in
first line treatment in patients with advanced NSCLC with non-squamous histology.
The epidermal growth factor receptor (EGFR) protein activation leads to TK activation and
results in cell proliferation, motility, adhesion, invasion, survival, and angiogenesis. The
EGFR is over expressed in many solid tumors, including non-small cell lung cancer (NSCLC),
and multiple studies have suggested a shortened survival in NSCLC patients whose tumor over
expresses EGFR . Although studies using small-molecule TK inhibitors (TKIs) in NSCLC did not
meet efficacy endpoints, a phase III trial demonstrated the benefit of EGFR TKI monotherapy.
Patients with advanced NSCLC who have received 2 or 3 prior therapies were randomized to
erlotinib or placebo, and those receiving erlotinib demonstrated a survival benefit that led
to FDA approval of this drug in 2004.
The studies above clearly demonstrated a benefit to combining anti-angiogenic factors with
chemotherapy, and as a monotherapy using anti-EGFR agents, in patients with advanced NSCLC.
The potential benefit to simultaneously targeting these 2 pathways has been addressed in the
recurrent disease setting.
Vandetanib is a novel oral molecule (anilinoquinazoline) that has dual activity against both
the VEGFR and EGFR pathways. Specifically, this compound has potent and reversible inhibitory
activity against VEGFR-2 (KDR), VEGFR-3 (Flt-4), EGFR and RET . Vandetanib is a TKI and thus
acts through inhibition of ATP binding to the tyrosine kinase domains of these receptors.
Recombinant enzyme assays have demonstrated that vandetanib is highly selective for both
VEGFR-2 (IC50=40 nm) with only slightly lower affinity for VEGFR-3 (2.7 fold). EGFR tyrosine
kinase activity is inhibited with an IC50=500 nm. The results of a second-line setting phase
II trial were presented by Heymach et al at the ASCO meeting in 2006. In this trial, patients
were randomized to receive either docetaxel alone, or docetaxel with either 100mg or 300mg of
vandetanib. Patients with squamous cell histology, controlled brain metastases and prior
history of hemoptysis were allowed on study. The primary endpoint of prolongation of
progression-free survival (PFS) was met in the 100mg arm (Hazard Ratio(HR) 0.64, p=0.07).
There was no increased incidence of hemoptysis in patients receiving vandetanib, and no CNS
hemorrhage events were observed, and side effects commonly attributed to EGFR inhibition
(rash, diarrhea) were higher on the 300mg arm. Early combination studies suggest that in
patients with NSCLC, vandetanib is safe in combination with chemotherapy, may improve the
outcomes of chemotherapy when used at the 100 mg dose, and has activity as monotherapy at the
300mg dose. In addition, none of the observed hemorrhagic complications seen with bevacizumab
were observed, even in patients at high risk for this complication.
In this study, our main goal is to study the combination of docetaxel + carboplatin and
vandetanib, followed by a double-blind randomized assignment to maintenance therapy with
vandetanib 300 milligrams (mg) or placebo by mouth daily until disease progression to
determine if maintenance therapy can prolong progression-free survival. In addition to
clinical efficacy outcomes we will monitor for safety and tolerability, as well as explore
any differences in outcome based on age and gender.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|